NRIX

Company Overview — What Does Nurix Therapeutics, Inc. Do?

Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer. The company has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California. Nurix Therapeutics, Inc. (NRIX) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Arthur T. Sands and employs approximately 300 people. With a market capitalization of $1.5B, NRIX is one of the notable companies in the Healthcare sector.

Nurix Therapeutics, Inc. (NRIX) Stock Rating — Reduce (April 2026)

As of April 2026, Nurix Therapeutics, Inc. receives a Reduce rating with a composite score of 34.7/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.NRIX ranks #2,689 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Nurix Therapeutics, Inc. ranks #319 of 839 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

NRIX Stock Price and 52-Week Range

Nurix Therapeutics, Inc. (NRIX) currently trades at $15.51. The 52-week high for NRIX is $22.50, which means the stock is currently trading -31.1% from its annual peak. The 52-week low is $8.18, putting the stock 89.6% above its annual trough. Recent trading volume was 0 shares, suggesting relatively thin trading activity.

Is NRIX Overvalued or Undervalued? — Valuation Analysis

Nurix Therapeutics, Inc. (NRIX) carries a value factor score of 19/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 2.97x, versus the sector average of 2.69x. The price-to-sales ratio is 19.29x, compared to 1.64x for the average Healthcare stock.

At current multiples, Nurix Therapeutics, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Nurix Therapeutics, Inc. Profitability — ROE, Margins, and Quality Score

Nurix Therapeutics, Inc. (NRIX) earns a quality factor score of 23/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -43.7%, compared to the Healthcare sector average of -42.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -34.2% versus the sector average of -33.1%.

On a margin basis, Nurix Therapeutics, Inc. reports gross margins of 100.0%, compared to 71.3% for the sector. The operating margin is -510.5% (sector: -65.2%). Net profit margin stands at -471.9%, versus -54.1% for the average Healthcare stock. Revenue growth is running at -34.7% on a trailing basis, compared to 10.7% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

NRIX Debt, Balance Sheet, and Financial Health

Nurix Therapeutics, Inc. has a debt-to-equity ratio of 28.0%, compared to the Healthcare sector average of 31.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 7.02x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $247M.

NRIX has a beta of 1.26, meaning it is more volatile than the broader market — a $10,000 investment in NRIX would be expected to move 26.0% more than the S&P 500 on any given day. The stability factor score for Nurix Therapeutics, Inc. is 39/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Nurix Therapeutics, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Nurix Therapeutics, Inc. reported revenue of $83M and earnings per share (EPS) of $-3.05. Net income for the quarter was $-235M. Gross margin was 100.0%. Operating income came in at $-257M.

In FY 2025, Nurix Therapeutics, Inc. reported revenue of $84M and earnings per share (EPS) of $-3.05. Net income for the quarter was $-264M. Revenue grew 54.0% year-over-year compared to FY 2024. Operating income came in at $-286M.

In Q3 2025, Nurix Therapeutics, Inc. reported revenue of $8M and earnings per share (EPS) of $-1.03. Net income for the quarter was $-86M. Revenue grew -37.3% year-over-year compared to Q3 2024. Operating income came in at $-91M.

In Q2 2025, Nurix Therapeutics, Inc. reported revenue of $44M and earnings per share (EPS) of $-0.52. Net income for the quarter was $-43M. Revenue grew 264.3% year-over-year compared to Q2 2024. Operating income came in at $-48M.

Over the past 8 quarters, Nurix Therapeutics, Inc. has demonstrated a growth trajectory, with revenue expanding from $12M to $83M. Investors analyzing NRIX stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

NRIX Dividend Yield and Income Analysis

Nurix Therapeutics, Inc. (NRIX) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

NRIX Momentum and Technical Analysis Profile

Nurix Therapeutics, Inc. (NRIX) has a momentum factor score of 49/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 38/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 52/100 reflects moderate short selling activity.

NRIX vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Nurix Therapeutics, Inc. (NRIX) ranks #319 out of 839 stocks based on the Blank Capital composite score. This places NRIX in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.5/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.3/100, HOLOGIC INC (HOLX) with a score of 52.8/100, FONAR CORP (FONR) with a score of 53.0/100, and Royalty Pharma plc (RPRX) with a score of 53.4/100.

Comparing NRIX against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full NRIX vs S&P 500 (SPY) comparison to assess how Nurix Therapeutics, Inc. stacks up against the broader market across all factor dimensions.

NRIX Next Earnings Date

No upcoming earnings date has been announced for Nurix Therapeutics, Inc. (NRIX) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy NRIX? — Investment Thesis Summary

The quantitative profile for Nurix Therapeutics, Inc. suggests caution. The quality score of 23/100 flags below-average profitability. The value score of 19/100 indicates premium valuation. High volatility (stability score 39/100) increases portfolio risk.

In summary, Nurix Therapeutics, Inc. (NRIX) earns a Reduce rating with a composite score of 34.7/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on NRIX stock.

Related Resources for NRIX Investors

Explore more research and tools: NRIX vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare NRIX head-to-head with peers: NRIX vs AZN, NRIX vs SLGL, NRIX vs HOLX.